Vaxxas Receives $22 Million from HHS for Vaccine Patch Studies

October 7, 2020

The HHS Biomedical Advanced Research and Development Authority has awarded Vaxxas $22 million to conduct phase 1 studies of its COVID-19 vaccine patch.

The phase 1 trials in the U.S. and Australia will evaluate the ability of the company’s high-density micro-array patch (HD-MAP) to deliver both adjuvanted and unadjuvanted COVID-19 vaccines to more than 400 participants.

The patch has “shown the potential to transform vaccine delivery with lower dose requirements, enabling more patient-doses to be manufactured more quickly from limited vaccine supply,” the company said.

View today's stories